Open AccessComparative study of in vitro activities of polymyxin B commercial products on Pseudomonas aeruginosa isolated from hospitalized patients
Author(s) -
Rezvan Goodarzi,
Farhad Farahani,
Mahdane Roshani,
Mohammad Taheri,
Babak Asghari
Publication year - 2021
Publication title -
ars pharmaceutica/ars pharmaceutica
Language(s) - English
Resource type - Journals
eISSN - 2340-9894
pISSN - 0004-2927
DOI - 10.30827/ars.v62i3.17851
Subject(s) - polymyxin , polymyxin b , pseudomonas aeruginosa , microbiology and biotechnology , antibiotics , in vitro , antibacterial activity , chemistry , biology , bacteria , biochemistry , genetics
Polymyxin B has been applied as one of the last-resort antibiotics for the treatment of multidrug resistance among Gram-negative bacterial infections. Due to side effects such as renal toxicity, the use of polymyxin is associated with limitations. The present study evaluates in vitro antibacterial activity of a number of polymyxin B commercial products against Pseudomonas aeruginosa.
Methods: This study included 63 non-duplicated P. aeruginosa isolates examined for in vitro polymyxin B susceptibility testing using the following powder disks: polymyxin B sulfate, otosporin, Poly-Mxb, and Myxacort. MIC50 and MIC90 have also been identified for polymyxin B antibiotics.
Results: Myxacort had functional activity against most P. aeruginosa isolates, and only seven isolates had a relatively high MIC. The activities of Poly-MXb and Myxacort were the same as otosporin.
Conclusions: Our findings revealed that the national generic polymyxin B product (Myxacort), and two external products (Otosporin, Poly-MXb) are similar in terms of microbiological activity.